Anti-amyloid-beta immunotherapy in Alzheimer's disease: relevance of transgenic mouse studies to clinical trials.
about
Methylene blue reduces aβ levels and rescues early cognitive deficit by increasing proteasome activityGermline humanization of a murine Aβ antibody and crystal structure of the humanized recombinant Fab fragmentProtective effects of low-intensity pulsed ultrasound on aluminum-induced cerebral damage in Alzheimer's disease rat model.Increased expression of the homologue of enhancer-of-split 1 protects neurons from beta amyloid neurotoxicity and hints at an alternative role for transforming growth factor beta1 as a neuroprotectorCurrent neuroimaging techniques in Alzheimer's disease and applications in animal modelsNext-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials.Novel amyloid-beta specific scFv and VH antibody fragments from human and mouse phage display antibody librariesAntibodies targeted to the brain with image-guided focused ultrasound reduces amyloid-beta plaque load in the TgCRND8 mouse model of Alzheimer's diseaseChronic delivery of antibody fragments using immunoisolated cell implants as a passive vaccination toolMidkine as a factor to counteract the deposition of amyloid β-peptide plaques: in vitro analysis and examination in knockout mice.Combination therapy prevents amyloid-dependent and -independent structural changes.Activation of matrix metalloproteinases following anti-Aβ immunotherapy; implications for microhemorrhage occurrence.Diverse inflammatory responses in transgenic mouse models of Alzheimer's disease and the effect of immunotherapy on these responses.Neuroinflammation in the aging down syndrome brain; lessons from Alzheimer's disease.Amyloid-β immunization enhances neurogenesis and cognitive ability in neonatal mice.Alzheimer's disease and the amyloid cascade hypothesis: a critical review.Microglia in Alzheimer brain: a neuropathological perspective.Tau-Directed Immunotherapy: A Promising Strategy for Treating Alzheimer's Disease and Other Tauopathies.Cessation of neoangiogenesis in Alzheimer's disease follows amyloid-beta immunizationAmyloid-beta expression in retrosplenial cortex of triple transgenic mice: relationship to cholinergic axonal afferents from medial septum.Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies.Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins.Immunotherapy for the treatment of Alzheimer's disease: amyloid-β or tau, which is the right target?Antibody-conjugated, dual-modal, near-infrared fluorescent iron oxide nanoparticles for antiamyloidgenic activity and specific detection of amyloid-β fibrils.Amyloid reduction by amyloid-beta vaccination also reduces mouse tau pathology and protects from neuron loss in two mouse models of Alzheimer's disease.Correlated inflammatory responses and neurodegeneration in peptide-injected animal models of Alzheimer's disease.A changing perspective on the role of neuroinflammation in Alzheimer's disease.Intracerebral immune complex formation induces inflammation in the brain that depends on Fc receptor interaction.Inhibition of RhoA GTPase and the subsequent activation of PTP1B protects cultured hippocampal neurons against amyloid β toxicity.Future Trends in the Pharmacogenomics of Brain Disorders and Dementia: Influence of APOE and CYP2D6 Variants.State-of-the-art of microbubble-assisted blood-brain barrier disruption
P2860
Q24634209-BF0014AC-C5BB-401D-8789-7E8B1D84D6D5Q27646600-78CF6522-5DFB-4266-839D-0661E09C382CQ30413664-2991631D-18AE-49E3-A946-9121B0D69BC5Q30460471-F45D7D22-82A8-4EDE-B698-E6E90282B3EDQ30576714-F1512EBE-7177-4E2A-B4C9-461BB6650B80Q30578913-FF407826-0807-4628-8400-FA14CA062569Q33572338-23B9D21F-817F-4891-8E16-C260FD3FD706Q33582089-ECE44DC0-2EA8-42D5-9B20-940F9DAC5EEBQ33886377-DF9EFF46-BF9E-4D9E-BE0C-6B033372C9F0Q34506576-C8F71538-D4BA-4980-867C-1D481AE7AD58Q34982179-64CB5C76-DA85-44AB-A4D1-6A80ADD1F4B0Q35240865-EAFA5343-D291-4346-9522-79B467F52BACQ35581445-CE84B5C0-9748-411E-8DCA-205C08C6084AQ35791628-31D8F587-9828-4CAF-B091-DF8F30B6DF11Q35792042-F772D0D4-B4CD-4E08-A422-9793D5CCDAA3Q35855587-39ED12DC-9CE3-424A-A628-AF94BC104C93Q35986371-A131D174-2C4D-433E-9E1E-54219D27F57DQ36558485-DF69A869-43C7-4B60-A6BD-C9A66943BA05Q36644869-D6A20258-0395-445C-AC51-87304CA1C9E0Q37442426-727B858A-89DE-4BFA-B87F-698014B8EEF9Q38079317-0B3AF62B-C239-4BBA-BAB4-36FFB5549170Q38122150-2BA8D712-F38F-4D18-BD6C-F06C923843B3Q38912261-CEE4E983-1AFE-45C6-8D83-0B4CF8C60FE9Q39066716-5F5F7ADE-DFE2-4567-B84B-3B1BAEF5669DQ40598120-76B9D5DC-3A7E-4F30-A9B8-7641AB0D61D3Q41266058-A1857FE2-4008-4A47-933C-6AD7FBA4DAAFQ42247119-50BFE865-AD1F-4D84-9BF9-4F8EC8C0459BQ42325913-4B8F00C1-191D-4817-9034-C77E812F91E8Q42602562-CE2FC10D-4CA8-436A-ADCD-7C4B60033A42Q55266735-70A0081A-1C70-4FAC-BBC0-C6972E2BB04FQ58796703-E4FA177C-4FCF-49EC-911F-A0060A21A14B
P2860
Anti-amyloid-beta immunotherapy in Alzheimer's disease: relevance of transgenic mouse studies to clinical trials.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Anti-amyloid-beta immunotherap ...... se studies to clinical trials.
@en
Anti-amyloid-beta immunotherap ...... se studies to clinical trials.
@nl
type
label
Anti-amyloid-beta immunotherap ...... se studies to clinical trials.
@en
Anti-amyloid-beta immunotherap ...... se studies to clinical trials.
@nl
prefLabel
Anti-amyloid-beta immunotherap ...... se studies to clinical trials.
@en
Anti-amyloid-beta immunotherap ...... se studies to clinical trials.
@nl
P2860
P356
P1476
Anti-amyloid-beta immunotherap ...... use studies to clinical trials
@en
P2093
Donna M Wilcock
P2860
P304
P356
10.3233/JAD-2008-15404
P577
2008-12-01T00:00:00Z